These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 27221530)

  • 1. Combinations of Oseltamivir and T-705 Extend the Treatment Window for Highly Pathogenic Influenza A(H5N1) Virus Infection in Mice.
    Marathe BM; Wong SS; Vogel P; Garcia-Alcalde F; Webster RG; Webby RJ; Najera I; Govorkova EA
    Sci Rep; 2016 May; 6():26742. PubMed ID: 27221530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycophenolic mofetil, an alternative antiviral and immunomodulator for the highly pathogenic avian influenza H5N1 virus infection.
    Cho J; Yi H; Jang EY; Lee MS; Lee JY; Kang C; Lee CH; Kim K
    Biochem Biophys Res Commun; 2017 Dec; 494(1-2):298-304. PubMed ID: 29017920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.
    Ilyushina NA; Hoffmann E; Salomon R; Webster RG; Govorkova EA
    Antivir Ther; 2007; 12(3):363-70. PubMed ID: 17591026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination Therapy with Oseltamivir and Favipiravir Delays Mortality but Does Not Prevent Oseltamivir Resistance in Immunodeficient Mice Infected with Pandemic A(H1N1) Influenza Virus.
    Baz M; Carbonneau J; Rhéaume C; Cavanagh MH; Boivin G
    Viruses; 2018 Nov; 10(11):. PubMed ID: 30400276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice.
    Ilyushina NA; Hay A; Yilmaz N; Boon AC; Webster RG; Govorkova EA
    Antimicrob Agents Chemother; 2008 Nov; 52(11):3889-97. PubMed ID: 18725448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination effects of peramivir and favipiravir against oseltamivir-resistant 2009 pandemic influenza A(H1N1) infection in mice.
    Park S; Kim JI; Lee I; Lee S; Hwang MW; Bae JY; Heo J; Kim D; Jang SI; Kim H; Cheong HJ; Song JW; Song KJ; Baek LJ; Park MS
    PLoS One; 2014; 9(7):e101325. PubMed ID: 24992479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice.
    Smee DF; Hurst BL; Wong MH; Bailey KW; Morrey JD
    Antimicrob Agents Chemother; 2009 May; 53(5):2120-8. PubMed ID: 19273672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses.
    Kiso M; Takahashi K; Sakai-Tagawa Y; Shinya K; Sakabe S; Le QM; Ozawa M; Furuta Y; Kawaoka Y
    Proc Natl Acad Sci U S A; 2010 Jan; 107(2):882-7. PubMed ID: 20080770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination activity of neuraminidase inhibitor oseltamivir and α-tocopherol in influenza virus A (H3N2) infection in mice.
    Galabov AS; Mileva M; Simeonova L; Gegova G
    Antivir Chem Chemother; 2015 Aug; 24(3-4):83-91. PubMed ID: 27341844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simvastatin and oseltamivir combination therapy does not improve the effectiveness of oseltamivir alone following highly pathogenic avian H5N1 influenza virus infection in mice.
    Belser JA; Szretter KJ; Katz JM; Tumpey TM
    Virology; 2013 Apr; 439(1):42-6. PubMed ID: 23453580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice.
    Smee DF; Hurst BL; Wong MH; Bailey KW; Tarbet EB; Morrey JD; Furuta Y
    Antimicrob Agents Chemother; 2010 Jan; 54(1):126-33. PubMed ID: 19901093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of laninamivir octanoate in mice with advanced inflammation stage caused by infection of highly lethal influenza virus.
    Tomozawa T; Hoshino K; Yamashita M; Kubo S
    J Infect Chemother; 2019 Aug; 25(8):584-588. PubMed ID: 30935767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined efficacy of oseltamivir, isoprinosine and ellagic acid in influenza A(H3N2)-infected mice.
    Pavlova EL; Simeonova LS; Gegova GA
    Biomed Pharmacother; 2018 Feb; 98():29-35. PubMed ID: 29241072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous peramivir inhibits viral replication, and leads to bacterial clearance and prevention of mortality during murine bacterial co-infection caused by influenza A(H1N1)pdm09 virus and Streptococcus pneumoniae.
    Onishi M; Kitano M; Taniguchi K; Homma T; Kobayashi M; Yoshinaga T; Naito A; Sato A
    Antiviral Res; 2015 May; 117():52-9. PubMed ID: 25752738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses.
    Govorkova EA; Leneva IA; Goloubeva OG; Bush K; Webster RG
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2723-32. PubMed ID: 11557461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus.
    Tarbet EB; Vollmer AH; Hurst BL; Barnard DL; Furuta Y; Smee DF
    Arch Virol; 2014 Jun; 159(6):1279-91. PubMed ID: 24311151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection.
    Fukao K; Noshi T; Yamamoto A; Kitano M; Ando Y; Noda T; Baba K; Matsumoto K; Higuchi N; Ikeda M; Shishido T; Naito A
    J Antimicrob Chemother; 2019 Mar; 74(3):654-662. PubMed ID: 30476172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
    Sidwell RW; Barnard DL; Day CW; Smee DF; Bailey KW; Wong MH; Morrey JD; Furuta Y
    Antimicrob Agents Chemother; 2007 Mar; 51(3):845-51. PubMed ID: 17194832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rimantadine and oseltamivir demonstrate synergistic combination effect in an experimental infection with type A (H3N2) influenza virus in mice.
    Galabov AS; Simeonova L; Gegova G
    Antivir Chem Chemother; 2006; 17(5):251-8. PubMed ID: 17176629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo activities of T-705 and oseltamivir against influenza virus.
    Takahashi K; Furuta Y; Fukuda Y; Kuno M; Kamiyama T; Kozaki K; Nomura N; Egawa H; Minami S; Shiraki K
    Antivir Chem Chemother; 2003 Sep; 14(5):235-41. PubMed ID: 14694986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.